Genmab news

29 September 2025
Genmab Acquires Merus for $8 Billion, Boosting Pipeline
Acquisition adds petosemtamab to Genmab's portfolio, aiming for 2027 launch. Expected to enhance growth and EBITDA by 2029.

What's Genmab up to in Europe?

Find out with chemXplore Analytics